Does osimertinib treatment discriminate young patients?
Sign Up to like & getrecommendations! Published in 2019 at "Journal of thoracic disease"
DOI: 10.21037/jtd.2019.08.118
Abstract: Osimertinib (AZD9291 or TAGRISSO™) is a third-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) developed to overcome T790M-induced resistance, which accounts for approximately 60% of resistant cases after 1 st generation EGFR-TKI treatment. Beyond… read more here.
Keywords: treatment discriminate; treatment; osimertinib treatment; young patients ... See more keywords